Abstract 232: Initiating Empagliflozin vs. Glucagon-like Peptide 1 Receptor Agonists is Associated With Lower Healthcare Cost of Care Among Patients With Type 2 Diabetes and Cardiovascular Disease
Abstract
Background:
The 2019 ADA’s Standards of Medical Care in Diabetes recommend use of SGLT-2 inhibitor (SGLT-2i) or GLP-1 receptor agonist (GLP-1RA) as one of the six drug classes after metformin (MET) in type 2 diabetes (T2D) patients, and is recommended as the treatment of choice among patients with cardiovascular disease (CVD; empagliflozin [EMPA] and liraglutide showing stronger evidence). CVD benefits of empagliflozin and GLP-1 RAs have been demonstrated in clinical trials; however, the impact on all-cause (AC) healthcare costs has not been studied.
Methods:
This retrospective cohort study utilized an US based, commercial claims database (IQVIA Pharmetrics Plus) to identify patients with T2D and CVD who initiated empagliflozin or a GLP-1 RA between 08/01/2014 - 12/31/2016. First prescription date (index date) for empagliflozin or a GLP-1 RA was used to classify patients into study cohorts. During a post-index period of up to 1 year, AC costs were computed on a per patient per month (PPPM) basis; and evaluated using generalized linear models that controlled for pre-index covariates. A sub-analysis comparing AC costs among patients who initiated second-line treatment with empagliflozin or a GLP-1 RA after metformin monotherapy, was also conducted.
Results:
As compared to the GLP-1 RA cohort (N = 1376), patients in the empagliflozin cohort (N= 441) were more likely to be males, had a lower Charlson comorbidity score, higher rates of dyslipidemia, and lower rates of obesity in…
How strong is the evidence?
Evidence Hub reads this as a cohort study, done in people. Its evidence level is 3 of 5 (Moderate · trial / cohort / secondary analysis). Trials without a large randomized design, cohorts and secondary analyses give moderate evidence. Reported size: 1,376 participants or records.
Read the paper
Related studies
- The Role of AMPK Activation for Cardioprotection in Doxorubicin-Induced Cardiotoxicity
- Hypoglycemic medicines in the treatment of Alzheimer’s disease: Pathophysiological links between AD and glucose metabolism
- Isorhamnetin Reduces Glucose Level, Inflammation, and Oxidative Stress in High-Fat Diet/Streptozotocin Diabetic Mice Model
- Modulating Sirtuin Biology and Nicotinamide Adenine Diphosphate Metabolism in Cardiovascular Disease—From Bench to Bedside
- Characterization of the SGLT2 Interaction Network and Its Regulation by SGLT2 Inhibitors: A Bioinformatic Analysis
- Early Treatment with Empagliflozin and GABA Improves β-Cell Mass and Glucose Tolerance in Streptozotocin-Treated Mice
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.